PTX Media related, page-1592

First 1592 Last

Share
Profile

Follow
dalts66

4,361 Posts.

2034

01/06/24

17:09

Post #: 74119437
Share

Originally posted by Shellbell: ↑

As those who are familiar with PTX-100, our drug has the potential for broad applicability. The KRAS G12C-driven cancer space has become very congested with loads of biotechs targeting the KRAS-G12C protein to inhbit the KRAS oncogene directly (many without success). PTX is different in that it seeks to inhibit the downstream pathways.

At this stage, PTX is pursuing the cheapest and quickest route to the clinic to prove up the mechanism of action of PTX-100 which is trialing T-Cell Lymphoma. My thoughts are that the MoA has been established in our Phase 1B study via the PD-PK analysis - in other words PTX-100 does what it is meant to do within the body. The tricky bit with TCL is the fact that its like a basket full of indications in one. If PTX is able to prove that our drug is as efficacious for PTCL as it is for CTCL based on more patient responses in this indication, then we could be on a winner in more ways than one. The difference where we stand now with PTX-100 - the need for recruitment of patients at fewer lines of treatment and on a dosing regime optimised to PTCL - and where we might be in the early stages of Ph2, could be monumental.

We already have promising safety and efficacy data in breast and ovarian cancer. Trials were conducted prior to the most recent Ph1b and expansion trial. PTX also has the patent for the p27 biomarker. The FDA is keen to progress treatments in the orphan drug space as well as drugs that have promise across a broader number of indications. The more I read about PTX-100, small molecule drugs and the changing landscape, the more I think that PTX-100 could be a winner. Not only that, there are things going on in the background that are just not being officially disclosed, IMO. Whether ongoing research is related specificially to PTX-100 or not is impossible to know.

Expand

Nailed it. Great post. Again.

PTX Price at posting: 4.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

There are more pages in this discussion • 22 more messages in this thread...

First 1592 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 4.0¢		Change 0.001(2.56%)		Mkt cap ! $32.21M

Open	High	Low	Value	Volume
4.0¢	4.0¢	4.0¢	$8.763K	219.0K

Buyers (Bids)

No.	Vol.	Price($)
2	58342	3.9¢

Sellers (Offers)

Price($)	Vol.	No.
4.1¢	168410	3

View Market Depth

No.	Vol.	Price($)
2	58342	0.039
6	551544	0.038
8	387500	0.037
5	708916	0.036
4	303590	0.035

Price($)	Vol.	No.
0.041	168410	3
0.042	337500	2
0.043	504602	3
0.045	222151	4
0.047	13339	1

Last trade - 15.13pm 02/10/2024 (20 minute delay)

PTX (ASX) Chart

PTX Media related, page-1592

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

PTX Media related, page-1592

Top Stories

SPC to merge with Original Juice Co and Nature One Dairy

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News